newsfilter
← Latest News
GlobeNewswire·

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast